Corient Private Wealth
CRSP icon

Corient Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Corient Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
34,811
+21,679
+165% +$1.14M ﹤0.01% 1363
2025
Q4 		$689K Buy
13,132
+5,026
+62% +$301K ﹤0.01% 2114
2025
Q3 		$525K Buy
8,106
+3,387
+72% +$194K ﹤0.01% 1768
2025
Q2 		$230K Buy
+4,719
New +$183K ﹤0.01% 2151
2025
Q1 		– Sell
-8,827
Closed -$347K – 2320
2024
Q4 		$347K Sell
8,827
-365
-4% -$17.2K ﹤0.01% 1816
2024
Q3 		$432K Buy
9,192
+992
+12% +$50.3K ﹤0.01% 1820
2024
Q2 		$443K Sell
8,200
-658
-7% -$38.1K ﹤0.01% 1712
2024
Q1 		$604K Buy
8,858
+58
+0.7% +$4.15K ﹤0.01% 1539
2023
Q4 		$551K Sell
8,800
-546
-6% -$30.2K ﹤0.01% 1573
2023
Q3 		$424K Buy
9,346
+1,699
+22% +$87.7K ﹤0.01% 1576
2023
Q2 		$429K Sell
7,647
-232
-3% -$13.2K ﹤0.01% 1526
2023
Q1 		$356K Buy
7,879
+707
+10% +$34.3K ﹤0.01% 1524
2022
Q4 		$292K Buy
+7,172
New +$380K ﹤0.01% 1345

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corient Private Wealth's CRSP Position: Q1 2026 in Review

Corient Private Wealth increased its CRISPR Therapeutics (CRSP) stake by 165% in Q1 2026, buying an estimated $1.14M and bringing the position to 34,811 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Corient Private Wealth first reported a position in CRSP in Q4 2022 and has held it in 13 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Corient Private Wealth held 34,811 shares of CRISPR Therapeutics worth $1.66M as of Q1 2026.
  • Corient Private Wealth bought 21,679 CRISPR Therapeutics shares in Q1 2026, an estimated $1.14M.
  • CRISPR Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1363 holding.
  • Corient Private Wealth first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.